2024-10-22 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

### 1. Performance Comparison

Johnson & Johnson (JNJ), a multinational pharmaceutical, medical device, and consumer packaged goods company, has underperformed the S&P 500 (VOO) in the period considered. While JNJ has recorded a cumulative return of 35.69%, VOO has achieved a significantly higher return of 136.39%. This translates to a current relative divergence of -100.7, meaning JNJ is currently underperforming VOO by a large margin. 

### 2. Recent Price Fluctuation

JNJ's closing price is currently at $162.59. The stock has experienced a recent dip, as indicated by the 5-day moving average of $163.86 being higher than the closing price. The 20-day moving average ($161.88) and 60-day moving average ($162.56) suggest that the stock price is currently fluctuating around its recent historical averages.

### 3. Technical Indicators 

- **RSI (57.03):**  JNJ's RSI currently sits at 57.03, indicating that the stock is neither overbought nor oversold. 
- **PPO (0.16):** The PPO value of 0.16 suggests a positive momentum in the stock price.
- **Delta_Previous_Relative_Divergence (-2.49):**  The negative value indicates a slight downward trend in the stock's relative performance over the past 20 days.
- **Expected Return (0.0):**  The expected return of 0.0% indicates that JNJ is expected to perform similarly to the S&P 500 in the long term (2 years or more).

### 4. Recent Earnings & Outlook

JNJ's most recent earnings report (2024-07-25) showed an EPS of 1.95 and revenue of $22.45 billion. This result surpassed analysts' expectations, which is a positive sign for the company. 

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

Overall, the company has been consistently delivering stable and predictable earnings, indicating strong financial health and a solid business model.

### 5. News & Recent Issues

**Recent Market Outlook:**

* **Analyst Opinions:**  Many analysts remain bullish on JNJ, citing its strong brand recognition, diversified business model, and consistent dividend payouts.
* **Performance Highlights:** Despite the recent underperformance compared to the S&P 500, JNJ remains a large-cap dividend-paying stock with a strong track record. Its consistent dividend payments and steady growth make it an attractive option for income-seeking investors.

**Recent Issues:**

* **Lawsuits and Settlements:** JNJ has been facing numerous lawsuits related to its talcum powder products and opioid medications. While the company has reached several settlements, this issue remains a concern for investors.
* **Spin-Off of Consumer Health Business:** JNJ recently announced the spin-off of its consumer health business, Kenvue, which is expected to be completed in November 2023. This move is aimed at simplifying the company's structure and allowing each business to focus on its core strengths.

### 6. Summary

JNJ, while a financially sound and well-established company, has recently underperformed the S&P 500.  However, its strong brand, diversified business, and consistent earnings suggest potential for future growth. The recent spin-off of the consumer health business could further enhance the company's focus and potentially lead to improved performance. Investors should consider the ongoing legal issues and carefully weigh the risks and potential rewards before investing in JNJ. 
